Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: liquidity remains a cause for concern

September 10, 2019 7:41am

Markets are set to open lower

The Strange Case of Dr. Jekyll and Mr. Hyde might make for a great read, but it’s far less fun when the sector act like it’s their blueprint.

It's a daunting task to understand risk, seeing the unforeseen; when you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

Dow futures are UP +0.14% (+38 points), S&P futures are DOWN -0.01% (-0.01 points) and NASDAQ futures are DOWN -0.26% (-20 points)

Futures point to a lower open

European markets are also lower as Brexit standoff is enhanced by ECB meeting

Asia pacific markets are mixed as Chinese producer prices drop

Data docket: new Job Openings and Labor Turnover Survey (JOLTS), due at 10:00 a.m. ET.

Henry’omics:

Pressure of the market weighs on the cell and therapy sector!

Investors are being left in the dust of electronic trading.

Bottom line, signs of faltering sentiment and price movement are based on a perception of a spiraling Q3 forecast of earnings, LPS (loss-per-share) numbers and operating cash utilization.

From Monday’s evening post, “no real movement from the open. Where is the news of clinical data updates (?); the sector needs to be about “forward motion” and I am not hearing it. Too much quiet on the cell and gene therapy front lines.”

• The NASDAQ was down -15.64 or -0.19% to 8,087.44;

• The IBB closed down -0.41% while the XBI also closed down -0.15%;

• The close was positive with an A/D Line of 25/18 and 0 flat and 2 acquired;

• The range of the 25 upside was +0.22% (BLUE) to +16.81% (KOOL) while the 18 downside ranged from -0.25% (RENE.L) to -5.84% (AXGN);

• 10 out of the 25 upside had higher than the 3 month average volume;

• 6 out of the 18 downside had higher than the 3 month average volume;

Q3/19 to date:

In July, there were 9 positive, 1 holiday and 13 negative closes;
In August there had been 12 negative and 10 positive closes
September started with 3 positive, 1 holiday and 2 negative close

Companies in my headlights – It’s your decision; I provide an idea and context:

*** Let the machines and algorithms do their worst – there is always a purge after a surge ***

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.